WO2004099154A3 - Pyrazole-amides and sulfonamides as sodium channel modulators - Google Patents

Pyrazole-amides and sulfonamides as sodium channel modulators Download PDF

Info

Publication number
WO2004099154A3
WO2004099154A3 PCT/US2004/013530 US2004013530W WO2004099154A3 WO 2004099154 A3 WO2004099154 A3 WO 2004099154A3 US 2004013530 W US2004013530 W US 2004013530W WO 2004099154 A3 WO2004099154 A3 WO 2004099154A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
sulfonamides
pyrazole
amides
sodium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/013530
Other languages
French (fr)
Other versions
WO2004099154A2 (en
Inventor
Robert N Atkinson
Irene Drizen
Robert J Gregg
Michael F Gross
Michael E Kort
Lei Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to MXPA05011775A priority Critical patent/MXPA05011775A/en
Priority to CA002525325A priority patent/CA2525325A1/en
Priority to EP04751090A priority patent/EP1620405A2/en
Priority to JP2006514200A priority patent/JP2006525355A/en
Publication of WO2004099154A2 publication Critical patent/WO2004099154A2/en
Publication of WO2004099154A3 publication Critical patent/WO2004099154A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, wherein R1 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroarylalkyl; R4 is formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie) or formula (If); or formula (II), or a pharmaceutically acceptable salt, amide, ester or prodrug thereof, wherein R14 is formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), or formula (XII); modulate PN3 in mammals and are useful in treating pain in mammals.
PCT/US2004/013530 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators Ceased WO2004099154A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA05011775A MXPA05011775A (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators.
CA002525325A CA2525325A1 (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators
EP04751090A EP1620405A2 (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators
JP2006514200A JP2006525355A (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46698003P 2003-05-01 2003-05-01
US10/427,847 US20040220170A1 (en) 2003-05-01 2003-05-01 Pyrazole-amides and sulfonamides as sodium channel modulators
US10/427,847 2003-05-01
US10/838,087 US20050020564A1 (en) 2003-05-01 2004-05-03 Pyrazole-amides and sulfonamides as sodium channel modulators

Publications (2)

Publication Number Publication Date
WO2004099154A2 WO2004099154A2 (en) 2004-11-18
WO2004099154A3 true WO2004099154A3 (en) 2005-04-14

Family

ID=34139555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013530 Ceased WO2004099154A2 (en) 2003-05-01 2004-04-29 Pyrazole-amides and sulfonamides as sodium channel modulators

Country Status (2)

Country Link
US (2) US20040220170A1 (en)
WO (1) WO2004099154A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1999114B1 (en) * 2006-03-22 2015-07-22 F. Hoffmann-La Roche AG Pyrazoles as 11-beta-hsd-1
EP2465851A1 (en) * 2006-07-05 2012-06-20 Aventis Agriculture 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
WO2008008286A2 (en) * 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
RS54303B1 (en) * 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-MEMBER HETEROCYCLIC AMIDES AND RELATED UNITS
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
EP2241567A4 (en) 2008-02-13 2011-11-09 Eisai R&D Man Co Ltd Bicycloamine derivative
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
JP5411927B2 (en) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazole compounds as CCR1 antagonists
MX2010014234A (en) * 2008-06-19 2011-03-25 Astrazeneca Ab Pyrazole compounds 436.
EP2346868B1 (en) * 2008-09-26 2016-01-27 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
MY155497A (en) * 2008-11-19 2015-10-30 Merial Inc Compositions comprising an aryl pyrazole and/or a formamidine, methods and use thereof
US9173728B2 (en) 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
EP2491028B1 (en) 2009-10-21 2013-12-11 Boehringer Ingelheim International GmbH Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
EP2493875B1 (en) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Heterocyclic compounds as ccr1 receptor antagonists
CA2782384A1 (en) * 2009-12-08 2011-06-16 Boehringer Ingelheim International Gmbh Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
EP2655371B1 (en) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Pyrazolopiperidine compounds as ccr1 receptor antagonists
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
TWI579274B (en) 2012-04-20 2017-04-21 龍馬躍公司 Improved processes for the preparation of 1-aryl-5-alkyl pyrazole compounds
CR20190436A (en) 2012-10-02 2019-10-29 Bayer Cropscience Ag Heterocyclic compounds as pesticides
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
ES2654393T3 (en) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
JP6195684B2 (en) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Pyrazole compounds and their use as T-type calcium channel blockers
WO2016041892A1 (en) 2014-09-15 2016-03-24 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
JP2019504840A (en) * 2016-01-28 2019-02-21 ソルヴェイ（ソシエテ アノニム） Halogen-substituted diketone, pyrazole compound and method for producing pyrazole compound
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN110072521B (en) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 Pharmaceutical combination comprising a T-type calcium channel blocker
MA47409A (en) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd NEW PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112480007B (en) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 Synthetic method of 1,3-dimethyl-1H-pyrazole-4-carboxylic acid
CN118126023B (en) * 2024-02-18 2025-04-11 安徽中医药大学 Pyrazole amide compounds and preparation methods and applications thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
WO1999032454A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
WO2000069849A1 (en) * 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2001019798A2 (en) * 1999-09-17 2001-03-22 Cor Therapeutics Inc. INHIBITORS OF FACTOR Xa
WO2001057024A1 (en) * 2000-02-04 2001-08-09 University College London Blockade of voltage dependent sodium channels
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
WO1999032454A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
WO2000069849A1 (en) * 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2001019798A2 (en) * 1999-09-17 2001-03-22 Cor Therapeutics Inc. INHIBITORS OF FACTOR Xa
WO2001057024A1 (en) * 2000-02-04 2001-08-09 University College London Blockade of voltage dependent sodium channels
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KORDIK, C. P. ET AL: "Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 11(17), 2287-2290 CODEN: BMCLE8; ISSN: 0960-894X, 2001, XP002302830 *
LAM, PATRICK Y. S. ET AL: "Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants", JOURNAL OF MEDICINAL CHEMISTRY , 46(21), 4405-4418 CODEN: JMCMAR; ISSN: 0022-2623, 9 October 2003 (2003-10-09), XP002302831 *
MUTLIB, ABDUL E. ET AL: "P450-mediated metabolism of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole- 5-carboxamide (DPC 423) and its analogs to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes", CHEMICAL RESEARCH IN TOXICOLOGY , 15(1), 63-75 CODEN: CRTOEC; ISSN: 0893-228X, 2002, XP002302829 *
PINTO, DONALD J. P. ET AL: "Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)- [1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", JOURNAL OF MEDICINAL CHEMISTRY , 44(4), 566-578 CODEN: JMCMAR; ISSN: 0022-2623, 2001, XP002302828 *
PRUITT, JAMES R. ET AL: "Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2'- (aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY , 46(25), 5298-5315 CODEN: JMCMAR; ISSN: 0022-2623, 4 December 2003 (2003-12-04), XP002302832 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921350B2 (en) 2006-12-28 2014-12-30 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8975258B2 (en) 2006-12-28 2015-03-10 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts

Also Published As

Publication number Publication date
US20050020564A1 (en) 2005-01-27
US20040220170A1 (en) 2004-11-04
WO2004099154A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2004099154A3 (en) Pyrazole-amides and sulfonamides as sodium channel modulators
NZ527081A (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2000041669A3 (en) Benzimidazole vascular damaging agents
MXPA01008142A (en) Amide compounds and medicinal use thereof.
NZ589670A (en) Pyrrolidine inhibitors of iap
TW200609237A (en) Thienopyridine derivatives
WO2004010949A3 (en) Compounds active in spinigosine 1-phosphate signaling
HK1053831A1 (en) Kinase inhibitors as therapeutic agents
WO2004013100A3 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
MY141504A (en) Gamma secretase inhibitors
TW200420558A (en) Amide compounds
WO2003048140A1 (en) Azole compound and medicinal use thereof
ATE453631T1 (en) PNA MONOMER AND PRECURSOR
WO2002018334A3 (en) Sodium channel modulators
YU72804A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
TW200519087A (en) Novel gamma secretase inhibitors
WO2006023515A3 (en) Novel thiazole inhibitors of fructose 1,6-bisphosphatase
EP1798226A4 (en) triazole
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
CA3191532A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
MXPA05007296A (en) (2-carboxamido) (3-amino) thiophene compounds.
WO2002072009A3 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
CA2212007A1 (en) Pyridonecarboxylic acid derivatives substitued by a bicyclic amino group
MXPA05011775A (en) Pyrazole-amides and sulfonamides as sodium channel modulators.
AU2048292A (en) Certain heteroaryl substituted hydroxylamine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004751090

Country of ref document: EP

Ref document number: 2006514200

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011775

Country of ref document: MX

Ref document number: 2525325

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004751090

Country of ref document: EP